Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type.
Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- *Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles *
*Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of** development**, and molecule type. *
“*Diabetic Peripheral Neuropathy Pipeline Analysis*” by *DelveInsight *features the details around the Diabetic Peripheral Neuropathy pipeline landscape, unmet needs, and Diabetic Peripheral Neuropathy therapeutic assessment of the key pipeline therapies.
Some of the chief *Diabetic Peripheral Neuropathy Pipeline Highlights *
· *20+* key companies are working to strengthen the Diabetic Peripheral Neuropathy pipeline including the *Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green,* and several others.
· Diabetic Peripheral Neuropathy market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates.
· *15+* Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include *Ricolinostat, FE-SYHA1402*, etc.
· *Collaborations and Deals*
· *Pipeline Drug Profiles provided include:*
· Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
· Phases of development of *Diabetic Peripheral Neuropathy Drugs*
· Mechanism of Action
· Route of Administration
· Diabetic Peripheral Neuropathy Companies involved including originator, licensing companies, developer, investors, and others
· New molecular entity details
· Drug designations and other special status provided by regulatory authorities
· *Diabetic Peripheral Neuropathy* *Market Drivers* and Barriers
· *Diabetic Peripheral Neuropathy Therapeutics Market Landscape*
Request for *Diabetic Peripheral Neuropathy Pipeline Assessment** Sample Report*
Diabetic Neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs, and feet, it is known as Diabetic Peripheral Neuropathy.
*Diabetic Peripheral Neuropathy pipeline report* encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and discovery.
*Diabetic Peripheral Neuropathy Emerging Drugs ** *
· *FE-SYHA1402 *by* CSPC ZhongQi Pharmaceutical Technology Co., Ltd.*
*ZhongQi Pharmaceutical Technology *is conducting a multiple doses study to assess the safety, tolerability, pharmacokinetics of *SYHA1402 *in healthy candidates. This study comprises two parts: The objective of the food effect study (Part 1) is to evaluate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The aim of the multiple doses study (Part 2) is to examine the safety, tolerability, and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses.
· *VM202 *by *Helixmith*
*VM202 *(donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms - a configuration that closely mimics HGF productions in humans that is required for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wild-type human HGF proteins.
· *NYX-2925 *by *Aptinyx*
*NYX-2925 *is a novel, oral small molecule NMDA receptor modulator in development for chronic pain treatment. Dysregulation of glutamatergic circuits in the brain is required in the development of centralized chronic pain. NYX-2925 is in late-stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia.
· *LX9211 *by* Lexicon Pharmaceuticals*
*LX9211 *is a potent, orally delivered, selective small-molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with *Bristol Myers Squibb*. Preclinical data displayed central nervous system penetration and lessen in pain behaviour in models of neuropathic pain. *Lexicon *has exclusive research, development, and commercialization rights to LX9211 and additional compounds acting through AAK1.
For further product profiles, request @ *Diabetic Peripheral Neuropathy Pipeline Analysis Sample Report*
*Scope of **Diabetic Peripheral Neuropathy Drug Pipeline Report** *
· *Coverage: *Global
· *Major Players: 20+ Key Companies *
· *Diabetic Peripheral Neuropathy* *Prominent Players**: *Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, Helixmith Co., Ltd., Bayer, Aptinyx, Eliem Therapeutics (UK) Ltd., Lexicon Pharmaceuticals, WinSanTor, Inc, Haisco Pharmaceutical Group Co., Ltd., Eli Lilly and Company, Daiichi Sankyo Co., Ltd., Avazzia, Inc, POLYSAN Scientific & Technological Pharmaceutical Company, Achelios Therapeutics Inc, Applied Therapeutics, Bionevia Pharmaceuticals, Regenacy Pharmaceuticals, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals, and many others.
· *Key Drugs Profiles: 15+ Products *
· *Diabetic Peripheral Neuropathy Drugs** Profiles*: Ricolinostat, FE-SYHA1402, CBD, Engensis, BAY1817080, NYX-2925 50, ETX-018810, LX9211, WST-057 (4% pirenzepine), HSK16149, LY3016859, Mirogabalin, Electrical Stimulation, Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), AT 001, BNV-222, Amitriptyline/ketamine, and many others.
· *Phases:** *
· Diabetic Peripheral Neuropathy Therapies Late-stage (Phase III)
· Diabetic Peripheral Neuropathy Therapies (Phase II)
· Diabetic Peripheral Neuropathy Therapies (Phase I)
· Diabetic Peripheral Neuropathy Therapies Pre-clinical stage and Discovery candidates
· Discontinued and Inactive candidates
· *Molecule Types: *
· Small molecule
· Gene Therapies
· *Route of Administration:*
· Infusion
· Intradermal
· Intramuscular
· Intranasal
· Intravaginal
· Oral
· Parenteral
· Subcutaneous
· Topical
· *Product Types:*
· Mono
· Combination
· Mono/Combination
*Key Questions regarding Current **Diabetic Peripheral Neuropathy Drug Treatment Landscape** and Emerging Therapies Answered in the Pipeline Report *
· What are the current options for Diabetic Peripheral Neuropathy treatment?
· How many companies are developing therapies for the treatment of Diabetic Peripheral Neuropathy?
· How many Diabetic Peripheral Neuropathy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Diabetic Peripheral Neuropathy?
· What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Diabetic Peripheral Neuropathy market?
· Which are the dormant and discontinued products and the reasons for the same?
· What is the unmet need for current therapies for the treatment of Diabetic Peripheral Neuropathy?
· What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Diabetic Peripheral Neuropathy therapies?
· What are the key designations that have been granted for the emerging therapies for Diabetic Peripheral Neuropathy?
· How many patents are granted and pending for the emerging therapies for the treatment of Diabetic Peripheral Neuropathy?
*Table of Contents *
*1* *Introduction*
*2* *Executive Summary of Diabetic Peripheral Neuropathy*
*3* *Diabetic Peripheral Neuropathy Overview*
*4* *Diabetic Peripheral Neuropathy Pipeline Therapeutics*
*5* *Diabetic Peripheral Neuropathy Therapeutic Assessment*
*6* *Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective*
*7* *Diabetic Peripheral Neuropathy Late Stage Products (Phase III)*
7.1 Engensis: Helixmith Co., Ltd.
*8* *Diabetic Peripheral Neuropathy Mid Stage Products (Phase II)*
8.1 Aptinyx: NYX-2925
8.2 LX9211: Lexicon Pharmaceuticals
*9* *Diabetic Peripheral Neuropathy Early Stage Products (Phase I)*
9.1 FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
*9.2* SR419: SIMR (Australia) Biotech Pty Ltd.* *
*10* *Diabetic Peripheral Neuropathy Pre-clinical and Discovery Stage Products*
*11* *Diabetic Peripheral Neuropathy Inactive Products*
*12* *Diabetic Peripheral Neuropathy Comparative Analysis *
*13* *Diabetic Peripheral Neuropathy Key Companies*
*14* *Diabetic Peripheral Neuropathy Key Products*
*15* *Company-University Collaborations (Licensing/Partnering) Analysis*
*16* *Diabetic Peripheral Neuropathy Unmet Needs*
*17* *Diabetic Peripheral Neuropathy Market Drivers and Barriers*
*18* *Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion*
*19* *Diabetic Peripheral Neuropathy Analyst Views*
*20* *Appendix*
*Browse Detailed TOC, Emerging Drugs and Key Companies @ **Diabetic Peripheral Neuropathy Pipeline Analysis Report*
*Related Reports *
· *Diabetic Peripheral Neuropathy Market Analysis *
DelveInsight's Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
· *Diabetic Peripheral Neuropathy Epidemiology Forecast Analysis *
DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in 7MM.* *
· *Dementia with Diabetes Market Analysis *
DelveInsight's Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
· *Diabetic Foot Market Analysis *
DelveInsight's Diabetic Foot Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
· *Diabetic Gastroparesis Market Analysis *
DelveInsight's Diabetic Gastroparesis Market Research Report presents a detailed analysis of the market listing Diabetic Gastroparesis Epidemiology, Drug therapies, market trends in 7MM.
· *Diabetic Kidney Disease Market Analysis *
DelveInsight's Diabetic Kidney Disease (DKD) Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
· *Diabetes Market Analysis *
DelveInsight's Diabetes Market Insights, Epidemiology, and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.
*About **DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
CONTACT: Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com